Dianthus Reports Q1 Revenue of $463,000, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy DNTH?
Reports Q1 revenue $463,000, consensus $358,690. "Q1 of this year was a pivotal period for Dianthus as we were able to make an early GO decision in PART A of the claseprubart CIDP CAPTIVATE study. In CAPTIVATE, we targeted 40 patients completing Part A and a response rate of approximately 50% based on precedent set with aC1s inhibition. We were able to make an early GO decision after 20 confirmed responders were identified with less than the 40 planned participants completing Part A. Claseprubart potency and early efficacy and safety results in CAPTIVATE Part A further build our confidence in claseprubart as a potentially best-in-disease therapy for neuromuscular diseases," said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. "We are also excited to announce the first three priority indications selected for DNTH212, our first-in-class bifunctional fusion protein and next potential best-in-disease pipeline therapeutic: Sjogren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis. These are areas of high unmet need, where compelling biological rationale and clinical data support the complementary potential of targeting both BDCA2 and BAFF/APRIL to drive differentiated efficacy compared to single-mechanism approaches. Together, these indications represent a strong foundation for establishing a synergistic rheumatology franchise around DNTH212, alongside the synergistic neuromuscular franchise we are building with claseprubart in gMG, CIDP and MMN."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNTH
Wall Street analysts forecast DNTH stock price to fall
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 86.710
Low
46.00
Averages
77.00
High
125.00
Current: 86.710
Low
46.00
Averages
77.00
High
125.00
About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Leads Biolabs Partners with Dianthus to Advance LBL-047 Clinical Development
- Clinical Development Strategy: Leads Biolabs' partner, Dianthus Therapeutics, has prioritized Sjögren's disease, systemic lupus erythematosus, and dermatomyositis for the clinical development of LBL-047, highlighting a commitment to addressing high unmet medical needs and potentially enhancing the company's market position in autoimmune diseases.
- Funding Support: In March 2026, Dianthus completed an upsized public offering, raising approximately $719 million, which provides a robust capital foundation for the global development of LBL-047, thereby strengthening its growth potential in the competitive biopharmaceutical market.
- Clinical Trial Progress: The Phase 1 study of LBL-047 was initiated in December 2025, with top-line results from healthy volunteers expected in the second half of 2026; successful completion of this phase will provide critical data to support further clinical development in prioritized indications.
- Global Partnership Agreement: The exclusive global partnership agreement between Leads Biolabs and Dianthus, with a potential deal value of up to $1 billion, indicates the company's intent to expand in the global market, aiming to maximize the clinical and commercial potential of LBL-047 through collaborative development.
See More
Leads Biolabs Partners with Dianthus to Advance LBL-047 Clinical Development
- Clinical Development Strategy: Leads Biolabs' partner, Dianthus Therapeutics, has prioritized Sjögren's disease, systemic lupus erythematosus, and dermatomyositis for the clinical development of LBL-047, highlighting a commitment to addressing high unmet medical needs, which may enhance the company's market share in autoimmune diseases.
- Funding Support: Dianthus completed an upsized public offering in March 2026, raising approximately $719 million, providing a robust financial foundation for the global development of LBL-047, which is expected to accelerate clinical trial processes and boost investor confidence.
- Clinical Trial Progress: The Phase 1 study of LBL-047 was initiated in December 2025, with top-line results from healthy volunteers anticipated in the second half of 2026, which will provide critical data for subsequent clinical development and further validate its application potential in autoimmune diseases.
- Global Partnership Agreement: The exclusive global partnership agreement between Leads Biolabs and Dianthus, with a potential deal value of up to $1 billion, indicates the company's strategic positioning in the global market, aiming to maximize the clinical and commercial potential of LBL-047 through collaboration.
See More
Dianthus Therapeutics Q1 Earnings Beat Expectations
- Earnings Highlights: Dianthus Therapeutics reported a Q1 GAAP EPS of -$0.85, beating expectations by $0.23, indicating some improvement in financial management, although overall revenue fell 60.3% year-over-year to $0.46M, reflecting ongoing market challenges.
- Strong Cash Position: As of March 31, 2026, Dianthus holds approximately $1.2 billion in cash, cash equivalents, and investments, projected to sustain operations into 2030, enhancing its flexibility in R&D and market expansion.
- Positive Market Reaction: Following the FDA's agreement to proposed changes in its lead program, Dianthus's stock price rose, indicating increased market confidence in the company's future prospects, which may attract more investor interest.
- Successful Upsized Offering: Dianthus successfully priced a $625 million public offering at $81 per share, demonstrating investor recognition of its long-term strategy and providing robust funding support for future R&D and market initiatives.
See More
Dianthus Grants Equity Awards to New Employees
- Equity Award Program: On May 1, 2026, Dianthus Therapeutics granted a total of 135,000 non-qualified stock options to six newly hired non-executive employees, with an exercise price of $87.42 per share, aimed at attracting top talent and strengthening the team.
- Grant Conditions: The stock options were approved by the company's independent Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4), highlighting the company's strategic focus on attracting and retaining talent.
- Vesting Arrangement: The options vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal monthly installments over the following 36 months, which incentivizes long-term employee retention and alignment with company growth.
- Company Background: Dianthus Therapeutics is dedicated to developing next-generation therapies for severe autoimmune diseases, backed by an experienced team of biotech and pharmaceutical executives committed to delivering transformative medicines, enhancing the company's competitive position in the biotech sector.
See More
Dianthus Therapeutics CFO Sells Shares for Profit
- Executive Stock Sale: On April 9, 2026, Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares of common stock for approximately $739,000, reflecting a liquidity management strategy amid rising stock prices.
- Option Exercise and Sale: The transaction was executed under a Rule 10b5-1 plan, resulting in Savitz's direct ownership dropping to zero, while he retains 71,776 unexercised options, indicating ongoing confidence in the company's future.
- Positive Market Reaction: Following the announcement of favorable interim results for its lead drug candidate claseprubart, Dianthus's stock surged in March, leading to a proposed $400 million secondary offering that ultimately raised $719 million, showcasing strong market confidence in its R&D prospects.
- Company Overview and Strategy: Dianthus focuses on developing monoclonal antibodies for severe autoimmune and inflammatory diseases, with its clinical-stage DNTH103 targeting various rare conditions, aiming to leverage innovative biologic therapies to meet unmet medical needs and strengthen its competitive position in the specialty therapeutics market.
See More
Dianthus Therapeutics CFO Sells Shares in Major Transaction
- Executive Stock Sale: On April 9, 2026, Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares of common stock for approximately $739,000, marking a complete divestment of his direct holdings and indicating a potential lack of confidence in the stock.
- Option Exercise and Sale: The transaction was structured as an option exercise and immediate sale, involving only direct holdings without participation from trusts or other entities, which signifies a total loss of direct control over his shares.
- Future Potential Retained: Despite selling all direct shares, Savitz retains 71,776 stock options that can be converted into common stock in the future, suggesting he may still have confidence in the company's long-term prospects.
- Market Response and Financing: Prior to Savitz's stock sale, Dianthus attracted significant institutional investment due to positive clinical trial results, culminating in a successful $719 million secondary offering, reflecting strong market confidence in its R&D pipeline.
See More
Leads Biolabs Partners with Dianthus to Advance LBL-047 Clinical Development
- Clinical Development Strategy: Leads Biolabs' partner, Dianthus Therapeutics, has prioritized Sjögren's disease, systemic lupus erythematosus, and dermatomyositis for the clinical development of LBL-047, highlighting a commitment to addressing high unmet medical needs and potentially enhancing the company's market position in autoimmune diseases.
- Funding Support: In March 2026, Dianthus completed an upsized public offering, raising approximately $719 million, which provides a robust capital foundation for the global development of LBL-047, thereby strengthening its growth potential in the competitive biopharmaceutical market.
- Clinical Trial Progress: The Phase 1 study of LBL-047 was initiated in December 2025, with top-line results from healthy volunteers expected in the second half of 2026; successful completion of this phase will provide critical data to support further clinical development in prioritized indications.
- Global Partnership Agreement: The exclusive global partnership agreement between Leads Biolabs and Dianthus, with a potential deal value of up to $1 billion, indicates the company's intent to expand in the global market, aiming to maximize the clinical and commercial potential of LBL-047 through collaborative development.
See More
Leads Biolabs Partners with Dianthus to Advance LBL-047 Clinical Development
- Clinical Development Strategy: Leads Biolabs' partner, Dianthus Therapeutics, has prioritized Sjögren's disease, systemic lupus erythematosus, and dermatomyositis for the clinical development of LBL-047, highlighting a commitment to addressing high unmet medical needs, which may enhance the company's market share in autoimmune diseases.
- Funding Support: Dianthus completed an upsized public offering in March 2026, raising approximately $719 million, providing a robust financial foundation for the global development of LBL-047, which is expected to accelerate clinical trial processes and boost investor confidence.
- Clinical Trial Progress: The Phase 1 study of LBL-047 was initiated in December 2025, with top-line results from healthy volunteers anticipated in the second half of 2026, which will provide critical data for subsequent clinical development and further validate its application potential in autoimmune diseases.
- Global Partnership Agreement: The exclusive global partnership agreement between Leads Biolabs and Dianthus, with a potential deal value of up to $1 billion, indicates the company's strategic positioning in the global market, aiming to maximize the clinical and commercial potential of LBL-047 through collaboration.
See More
Dianthus Therapeutics Q1 Earnings Beat Expectations
- Earnings Highlights: Dianthus Therapeutics reported a Q1 GAAP EPS of -$0.85, beating expectations by $0.23, indicating some improvement in financial management, although overall revenue fell 60.3% year-over-year to $0.46M, reflecting ongoing market challenges.
- Strong Cash Position: As of March 31, 2026, Dianthus holds approximately $1.2 billion in cash, cash equivalents, and investments, projected to sustain operations into 2030, enhancing its flexibility in R&D and market expansion.
- Positive Market Reaction: Following the FDA's agreement to proposed changes in its lead program, Dianthus's stock price rose, indicating increased market confidence in the company's future prospects, which may attract more investor interest.
- Successful Upsized Offering: Dianthus successfully priced a $625 million public offering at $81 per share, demonstrating investor recognition of its long-term strategy and providing robust funding support for future R&D and market initiatives.
See More
Dianthus Grants Equity Awards to New Employees
- Equity Award Program: On May 1, 2026, Dianthus Therapeutics granted a total of 135,000 non-qualified stock options to six newly hired non-executive employees, with an exercise price of $87.42 per share, aimed at attracting top talent and strengthening the team.
- Grant Conditions: The stock options were approved by the company's independent Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4), highlighting the company's strategic focus on attracting and retaining talent.
- Vesting Arrangement: The options vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal monthly installments over the following 36 months, which incentivizes long-term employee retention and alignment with company growth.
- Company Background: Dianthus Therapeutics is dedicated to developing next-generation therapies for severe autoimmune diseases, backed by an experienced team of biotech and pharmaceutical executives committed to delivering transformative medicines, enhancing the company's competitive position in the biotech sector.
See More
Dianthus Therapeutics CFO Sells Shares for Profit
- Executive Stock Sale: On April 9, 2026, Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares of common stock for approximately $739,000, reflecting a liquidity management strategy amid rising stock prices.
- Option Exercise and Sale: The transaction was executed under a Rule 10b5-1 plan, resulting in Savitz's direct ownership dropping to zero, while he retains 71,776 unexercised options, indicating ongoing confidence in the company's future.
- Positive Market Reaction: Following the announcement of favorable interim results for its lead drug candidate claseprubart, Dianthus's stock surged in March, leading to a proposed $400 million secondary offering that ultimately raised $719 million, showcasing strong market confidence in its R&D prospects.
- Company Overview and Strategy: Dianthus focuses on developing monoclonal antibodies for severe autoimmune and inflammatory diseases, with its clinical-stage DNTH103 targeting various rare conditions, aiming to leverage innovative biologic therapies to meet unmet medical needs and strengthen its competitive position in the specialty therapeutics market.
See More
Dianthus Therapeutics CFO Sells Shares in Major Transaction
- Executive Stock Sale: On April 9, 2026, Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares of common stock for approximately $739,000, marking a complete divestment of his direct holdings and indicating a potential lack of confidence in the stock.
- Option Exercise and Sale: The transaction was structured as an option exercise and immediate sale, involving only direct holdings without participation from trusts or other entities, which signifies a total loss of direct control over his shares.
- Future Potential Retained: Despite selling all direct shares, Savitz retains 71,776 stock options that can be converted into common stock in the future, suggesting he may still have confidence in the company's long-term prospects.
- Market Response and Financing: Prior to Savitz's stock sale, Dianthus attracted significant institutional investment due to positive clinical trial results, culminating in a successful $719 million secondary offering, reflecting strong market confidence in its R&D pipeline.
See More
